Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a fixed-dose combination inhaler containing three active pharmaceutical ingredients: fluticasone furoate (an inhaled corticosteroid), umeclidinium bromide (a long-acting muscarinic antagonist), and vilanterol trifenatate (a long-acting β₂-adrenergic agonist).
How to Use Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Standard Usage Instructions
For oral inhalation only; use one inhalation once daily.
Administer at the same time each day.
After inhalation, rinse your mouth with water and do not swallow the rinse water. This helps reduce the risk of oropharyngeal candidiasis (thrush).
Strictly do not use more than once per day.
Maintenance Treatment for COPD
The recommended dose is 100 mcg fluticasone furoate, 62.5 mcg umeclidinium bromide, and 25 mcg vilanterol trifenatate (one inhalation) once daily.
Maintenance Treatment for Asthma
For the 100/62.5/25 mcg strength: One inhalation once daily.
For the 200/62.5/25 mcg strength: One inhalation once daily.
Dosage Adjustment for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Patients with Hepatic Impairment
Systemic exposure to fluticasone furoate may increase in patients with moderate or severe hepatic impairment.
Use with caution in patients with moderate to severe hepatic impairment.
Monitor patients for systemic corticosteroid effects (e.g., weight gain, hyperglycemia, osteoporosis).
Important Note: Concomitant use of this medication with potent CYP3A4 inhibitors should be avoided in patients with combined hepatic and renal impairment.
Special Drug Interactions
Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) may increase the risk of systemic corticosteroid effects and cardiovascular adverse reactions.
Use in Special Populations for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Elderly Patients
Based on available data, no dosage adjustment is required for elderly patients. However, the possibility of increased sensitivity in some elderly individuals cannot be excluded.
Pregnant Women
There are insufficient data to confirm the risks of this medication or its individual components in pregnant women.
In animal reproductive studies, fluticasone furoate and vilanterol trifenatate did not cause structural fetal abnormalities.
Lactating Women
It is currently unknown whether fluticasone furoate, umeclidinium bromide, or vilanterol trifenatate is excreted into human milk, or what effects these ingredients may have on breastfed infants.
Pediatric Patients
The efficacy of this medication has not been established in pediatric patients aged 17 years and younger; therefore, it is not indicated for this population.
